# Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan

> **NCT02747537** · PHASE2 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Pediatric Solid Tumors

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT02747537
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06-24
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-02-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Could not recruit participants for the study
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02747537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02747537, "Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02747537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*